% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • tek_jansen500 tek_jansen500 Dec 19, 2011 9:58 AM Flag

    Phase 3 results conference call

    Anyone listen? Could you post comments? I'm curious if something in the call explains why stock is down instead of up.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I can't listen but my guess is that the market expected superiority and all they got was non-inferiority? If you ask me, a shorter course of treatment with fewer doses that gives you fewer side effects and the same result is superior, but maybe others don't see it that way.

      • 1 Reply to markak1515
      • JN from Zacks. I've been out of this for a few months but looking for reenntry

        JNapodano Jason Napodano, CFA @
        @veritasphi Now it just looks like the drug is more convenient and safer. Nice, but doesn't drive home big sales numbers.
        25 minutes ago Favorite Retweet Reply

        JNapodano Jason Napodano, CFA @
        @veritasphi The data weren't quite as strong as I expected. It was a no-brainer when the drug was more powerful, more convenient, and safer.
        25 minutes ago

        JNapodano Jason Napodano, CFA
        I expected a better outcome from tedizolid in the primary endpoint (79.5%) vs. Zyvox (79.4%). Phase 2 data hinted at a number in the 90's.